

EG00229

Catalog No: tcsc3101



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

1210945-69-9

Formula:

$C_{19}H_{20}F_3N_7O_7S_3$

Pathway:

Protein Tyrosine Kinase/RTK

Target:

VEGFR

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 41.4 mg/mL (67.69 mM)

Observed Molecular Weight:

611.6

Product Description


EG00229 is the first small molecule inhibitor of the neuropilin-1 and VEGF-A interaction with an IC50 of inhibition of 8 μ M(125I-VEGF

binding to PAE/NRP1 cells).

IC50 value: 8 μ M [1]

Target: NRP1/VEGF-A inhibitor

EG00229 reduced VEGF-A-induced VEGFR2 tyrosine phosphorylation in HUVECs in a dose-dependent fashion, with a maximum inhibition of 34% at 100 μ M. EG00229 also significantly reduced VEGF-A induced migration of HUVECs. caused a partial inhibition of VEGF receptor activity and biological function, consistent with the current model for the role of NRP1 in VEGF function, in which NRP1 is required for optimal signaling and certain biological functions downstream of VEGFR2, particularly migration [1].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!